The former CEO of Reckitt Benckiser’s operations in South Korea has been jailed for seven years over the sale of humidifier disinfectants that have caused the deaths of around 100 people and left many more with permanent lung damage.

The Seoul Central District Court ruled on Jan. 6 that Shin Hyun-woo, head of the Korean Oxy subsidiary from 1991 to 2005, was guilty of accidental homicide and falsely advertising the toxic chemical product without conducting proper safety inspections.

The UK consumer goods group is just one of several firms linked to the deaths. Six executives at local retailers Lotte Mart and Homeplus were also given jail terms of three to five years.

Reckitt Benckiser withdrew its product from the market after South Korean authorities concluded the disinfectants were to blame for the deaths of several pregnant women from lung problems. Many households in the country use humidifiers in the dry winter season to put moisture back into the air.

It is believed between 90 and 100 people – mostly women and children – died as a result of the toxic disinfectants in what has been dubbed South Korea’s worst consumer products scandal. The company made a public apology last year and offered compensation to the families of those who died, as well as the hundreds more who have been suffered lasting damage.

The news comes less than one month after the Slough-headquartered group was fined a record 6 million Australian dollars for misleading consumers over the painkilling effects of Nurofen. Reckitt Benckiser was fined 1.7 million Australian dollars last April but the country’s consumer watchdog argued this was too low and appealed.

The court upheld the appeal on Dec. 16, increasing the penalty to ensure that Reckitt Benckiser and other “would-be wrongdoers think twice and decide not to act against the strong public interest”.

The Australian Competition and Consumer Commission (ACCC) said the company had profited substantially from deceiving consumers into believing that its Nurofen specific-pain products, which were available between 2011 and 2015 and sold at nearly twice the price of its standard version, were more effective. The specific-pain range claimed to target back pain, migraine, tension headache or period pain but they all contained the same active ingredient, ibuprofen lysine 342 mg.